相关实验视频
Updated: Feb 10, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.8K
[在慢性病中早期诊断和针对Klotho蛋白的向治疗的潜力]
Yifeng Li1, Guihong Chen2, Meijun Chen2
1Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Zhanjiang 524001. Liyif@gdmu.edu.cn.
概括
对于脏健康至关重要的克洛托 (KL) 蛋白在慢性脏疾病 (CKD) 中下降. 新的FGF-23结合和DUBTAC技术为敏感的KL检测和向的CKD疗法提供了潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 克洛托 (KL) 蛋白是一种重要的脏保护因子,具有多种器官保护功能,包括矿物代谢调节,抗炎和抗氧化作用以及抗衰老信号.
- 在早期慢性病 (CKD) 中,KL水平下降,与疾病严重程度相关,这表明其作为早期诊断生物标志物的有用性.
- 目前针对KL的治疗方法在临床转化方面面临挑战.
研究的目的:
- 探索敏感的Klotho检测和针对慢性病的有针对性的治疗干预的新策略.
- 调查工程纤维细胞生长因子-23 (FGF-23) 结合的潜力,用于增强的Klotho测试.
- 评估用于保护Klotho免受降解的双双基因酶向基因组 (DUBTAC) 技术的应用.
主要方法:
- 开发工程化FGF-23结合,显著增加对Klotho的亲和力.
- 调查导致Klotho无化和降解的内等质网膜 (ER) 相关降解 (ERAD) 途径.
- 应用DUBTAC技术来抑制Klotho的泛化并防止其降解.
主要成果:
- 设计的FGF-23结合表明对Klotho的亲和力增加了多达2300倍,使得高度敏感的测试开发成为可能.
- 持续的ERAD激活被确定为驱动Klotho降解的关键机制.
- 在保护Klotho免受无处不在和退化方面,DUBTAC技术显示出有前途的承诺.
结论:
- 工程FGF-23结合和KL向的DUBTAC技术的组合为敏感的Klotho检测和向治疗提供了一个有前途的双重方法.
- 这一创新策略对促进慢性病管理具有重大临床意义.
- 预计会加速对Klotho敏感检测和治疗策略的临床开发.
相关概念视频
01:25Chronic Kidney Disease I: Introduction
753
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
753
01:24Chronic Kidney Disease II: Clinical Manifestations
677
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
677
01:28Chronic Kidney Disease III: Interprofessional Care
483
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
483
01:18Chronic Kidney Disease IV: Nursing Management
404
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
404
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:24Chronic Obstructive Pulmonary Disease
2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K